TSLP signaling in breast-tumor cells is required for their growth in vitro and in vivo. Whether TSLP can be produced directly by human breast-tumor cells remains controversial 2,9 . To directly investigate the role of tumor-cell-derived TSLP in regulating breast-tumor progression, we generated TSLP-deficient 4T1 cells Tumors actively manipulate the immune response through the production of factors that attract immune cells and subsequently alter their ability to recognize and effectively remove the tumor. While this mechanism for evading the immune system is an important aspect of tumor survival, the factors that serve as primary growth factors for the tumor are less understood. Here we demonstrate a previously unknown mechanism by which breast-cancer cells manipulate tumor-infiltrating myeloid cells to maintain their survival. Tumor-derived interleukin 1α (IL-1α ), acting on infiltrating myeloid cells, induced the expression of a critical tumor survival factor, the cytokine TSLP. TSLP promoted the survival of the tumor cells through induction of the expression of the anti-apoptotic molecule Bcl-2. TSLP signaling was also required for metastasis to the lungs. These studies define a novel IL-1α -TSLP-mediated crosstalk between tumor-infiltrating myeloid cells and tumor cells in the control of metastatic breast cancer.
T SLP ('thymic stromal lymphopoietin'), a key cytokine that initiates and promotes the development of type 2 immunity 1 , has been linked to the progression of several human cancers, including breast, pancreatic, gastric and cervical cancer, and B cell lymphoma and myeloma [2] [3] [4] [5] [6] [7] . In breast cancer, TSLP can be produced by both human tumor cells and mouse tumor cells to promote tumor progression by generating type 2-biased inflammation in the tumor microenvironment 2, 8 . However, a published study has shown that TSLP expression by human breast tumors is not universal, which suggests the possibility of alternative sources of TSLP in breast cancer 9 . The possible source of TSLP in such tumor microenvironments was not fully investigated, and the identity of critical TSLP-responding cells was also not clear. Although TSLP has been suggested to have a role in promoting some of the human cancers mentioned above, several studies have pointed to an anti-tumor role for TSLP in skin, colon and early-stage breast cancer in mouse models, which emphasizes the need to understand the effect of TSLP on various cell types in tumor microenvironments [10] [11] [12] [13] . The TSLP receptor (TSLPR), composed of the TSLPR chain and the interleukin 7 receptor α -chain (IL-7Rα ), is widely expressed on various immune cells, including B cells, mast cells, macrophages, dendritic cells, basophils, CD4 + T cells, CD8 + T cells and regulatory T cells 14, 15 . TSLP signaling in different types of immune cells has been reported to affect various immune responses in mice and to control related human diseases 1 . Furthermore, TSLPR expression on non-hematopoietic cells, including airway and colonic epithelium, has also been seen, with expression regulated by local inflammation 13, 16, 17 .
TSLP is expressed mainly by epithelial cells in homeostatic conditions, and its expression is induced by inflammatory stimuli 14 . TSLP expression in epidermal keratinocytes and lung epithelial and smooth muscle cells results in pathological symptoms in atopic dermatitis and asthma [18] [19] [20] . Hematopoietic cells can also express TSLP, as dendritic cells can express TSLP after challenge with ligands for Toll-like receptors or with allergens 21, 22 . TSLP expression is upregulated in lung epithelial cells when the transcription factor NF-κ B is activated by IL-1, the cytokine TNF ('tumor-necrosis factor') or ligands for Toll-like receptors 23 .
IL-1α is a pleiotropic pro-inflammatory cytokine that is broadly associated with many inflammatory responses. After binding to its receptor IL-1R1, IL-1α triggers signaling cascades that activate NF-κ B and kinases of the MAPK family. IL-1α can be secreted by various cell types either constitutively or after cell damage or stimulation. IL-1α produced by tumor cells or by adjacent stromal cells has been associated with the development of many different human cancers through the stimulation of tumor-cell growth and the induction of vasculogenic factors 24 . In breast cancer, IL-1α has been reported expressed by human breast-tumor cells, and expression of an active form of IL-1α in the human breast-tumor cell line MCF-7 leads to increased tumor growth in vivo in a xenograft breast-tumor model 25, 26 .
We employed both orthotopic mouse models and autochthonous mouse models of metastatic breast cancer to study the role of TSLP in tumor progression. We found that TSLP served as an essential growth and survival factor for breast-tumor cells through its ability to induce expression of the anti-apoptotic molecule Bcl-2. Lack of TSLP signaling in breast-tumor cells led to profound regression of primary tumor growth and reduced metastasis to the lungs due to increased tumor-cell death. TSLP expression by myeloid cells, induced by tumor-derived IL-1α , was required for the survival of tumor cells. We also found that TSLP expression in the lungs, regardless of the source, was essential for the establishment and growth of metastases. The data provide novel mechanistic insights into the role of TSLP in breast tumor progression and suggest blockade of TSLP as a potential therapeutic strategy for breast cancer.
Articles NaTure ImmuNoLogy (a TSLP-expressing mouse breast-tumor cell line that gives rise to a disease that resembles metastatic human breast cancer) 8, 27 ( Supplementary Fig. 1a ). Interestingly, we found no difference in primary tumor size in wild-type mice given transplantation of TSLP-deficient 4T1 cells (generated with CRISPR-Cas9-GFP guide RNA 2-3; 4T1-Tslp -/-2-3 cells) relative to that of their counterparts given transplantation of TSLP-sufficient (control) 4T1 cells (4T1-M1 cells; M1 is a non-targeting guide RNA used as control for CRISPR-Cas9 targeting) ( Fig. 1a ), which indicated that TSLP produced by breast-tumor cells was not critical for primary tumor progression in vivo. Although TSLP deficiency did not affect tumor growth in mice, we found lower survival of 4T1-Tslp -/-2-3 tumor cells than of 4T1-M1 tumor cells in vitro ( Fig. 1b) , which suggested that a non-tumor source of TSLP regulates tumor survival in vivo. To test that hypothesis, we assessed TSLPR expression on breast-tumor cells and found expression of both TSLPR and IL-7Rα ( Fig. 1c ). Notably, human breast tumors from patients at stage I to stage III also expressed TSLPR, but non-tumor breast tissue did not ( Fig. 1d and Supplementary Fig. 1b ). Similar to primary human breast-tumor cells, the human breast-tumor-cell line MDA-MB 468 expressed TSLPR, while a non-tumor human breast epithelial-cell line (MCF10A) did not ( Supplementary Fig. 1c ). To assess the requirement for TSLP signaling in tumor-cell progres-sion in vivo, we generated TSLPR-deficient 4T1 cells (4T1-Crlf2 -/-4-6 cells, generated with CRISPR-Cas9-GFP guide RNA 4-6; called '4T1-Tslpr -/-4-6' cells here) ( Supplementary Fig. 1d ). Mice given transplantation of 4T1-Tslpr -/-4-6 cells displayed much smaller primary breast tumors than those of mice given transplantation of 4T1-M1 cells ( Fig. 1e ), which showed that direct TSLP signaling by the tumor was needed to maintain their growth in vivo. These data demonstrated a critical role for TSLP signaling in breast-tumor cells for their progression in vivo.
Non-tumor-derived TSLP from hosts is critical for regulating breast-tumor progression in vivo. To confirm the need for non-tumor-derived TSLP in tumor-cell progression in vivo, we transplanted TSLP-sufficient 4T1 tumor cells into TSLP-deficient (TSLP-KO) mice and found smaller primary breast tumors in those mice than in their wild-type counterparts ( Fig. 2a ), which confirmed a critical role for non-tumor-derived TSLP in maintaining primary tumor growth. To exclude the possibility that the lack of TSLP in non-tumor cells altered tumor-infiltrating T cells for elimination of the tumor, we assessed the frequency of various T cell populations in the tumor. We found no difference between the primary tumors of TSLP-KO tumor-bearing mice and those of wild-type tumor-bearing mice in the frequency of total T cells, proportion of CD4 + T cells 
Fig. 1 | TSLPR is expressed by breast-tumor cells, and TSLP signaling in breast-tumor cells is critical for tumor progression in the primary site. a,e,
Volume of the primary breast tumor on days 0-28 (horizontal axis) (left) and weight of the primary tumor at day 28 (right) after transplantation of 4T1-M1 or 4T1-Tslp -/-2-3 cells (a) or 4T1-M1 or 4T1-Tslpr −/− 4-6 cells (e) into wild-type mice (n = 4 host mice per group). b, Flow cytometry of 4T1-M1 and 4T1-Tslp -/-2-3 cells (above plots) after culture in vitro, assessed with fixable viability dye (FVD) and the apoptosis marker annexin V (left), and quantification of total annexin V-positive (AnnV + ) (dying) cells as at left (n = 3 cultures per group) (right). Numbers in outlined areas (left) indicate percent annexin Vpositive cells. c, Flow cytometry analyzing the expression of TSLPR (left) and IL-7Rα (right) on 4T1 tumor cells. IC (key), isotype-matched control antibody. d, Microscopy of human breast tumors from patients (among n = 12) with breast cancer at stage I, II or III (above images), assessing surface expression of TSLPR (left), and of a human breast tumor stained with isotype-matched control antibody (right). Scale bars, 10 μ m. Each symbol (a,b,e) represents an individual mouse (a,e) or culture (b); small horizontal lines indicate the mean ( ± s.e.m.). P values (above data points), unpaired, two-tailed t-test with 95% confidence intervals. Data are representative of three (a,b,e) or two (c,d) independent experiments.
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and CD8 + T cells, or expression of the co-inhibitory receptor PD-1 in CD4 + or CD8 + T cells ( Supplementary Fig. 2a -c), which indicated that the increased tumor-cell death was not due to increased recruitment of T cells to the tumor site. We next used an autochthonous breast-cancer model, MMTV-PyMT mice (called 'MTAG' here) 28 , to test our hypothesis. Unlike 4T1 cells, AT3 cells (a breast-tumor cell line generated from an MTAG primary tumor) 29 and tumor cells from MTAG primary tumors had very low expression of TSLP ( Fig. 2b ,c; gating strategy for tumor cells in the primary tumors of mice bearing '4T1-GFP' tumors (4T1 cells transduced with lentivirus expressing green fluorescent protein (GFP)) 30 and MTAG mouse primary tumors 31 , Supplementary Fig. 2d,e ). However, systemic concentrations of TSLP were higher in MTAG mice than in wild-type mice ( Fig. 2d ), which indicated that a non-tumor source of TSLP was involved in regulating tumor progression in this model. In addition, tumor growth in TSLP-deficient MTAG (MTAG-TSLP-KO) mice was lower than that of MTAG mice ( Fig. 2e ). Systemic blockade of TSLP with an antibody to TSLP, begun when tumors were palpable, significantly reduced primary breast-tumor growth in MTAG mice ( Fig. 2f ). These results demonstrated that TSLP produced by non-tumor cells was critical for tumor progression.
TSLP signaling in breast-tumor cells regulates tumor-cell survival.
We next investigated how TSLP signaling directly influenced tumor cells. We found that in in vitro conditions, both 4T1-Tslpr -/-4-6 tumor cells and 4T1-Tslp -/-2-3 tumor cells displayed lower viability than that of 4T1-M1 cells (Figs. 1b and 3a), whereas treating parental 4T1 cells with TSLP enhanced their viability through upregulation of the anti-apoptotic molecules Bcl-2 and Bcl-x L (Fig. 3b,c) . We observed similar results when we treated AT3 cells with TSLP ( Supplementary Fig. 3a,b ). Next we explored tumor-cell survival in the primary tumor in tumor-bearing mice (gating strategy, Supplementary Fig. 3c ). Interestingly, we observed decreased survival of only 4T1-Tslpr -/-4-6 cells (relative to that of 4T1-M1 cells), not of 4T1-Tslp -/-2-3 cells, in the primary tumor after they were transplanted into wild-type mice ( Fig. 3d ), which indicated that TSLP from non-tumor sources maintained tumor-cell survival in vivo. Notably, 4T1 cells transplanted into TSLP-KO mice displayed much lower survival in the primary tumor, with increased tumor-cell expression of cleaved caspase 3 and reduced tumor-cell expression of Bcl-2 and Bcl-x L , relative to that of their counterparts transplanted into wild-type mice ( Supplementary Fig. 3d and Fig. 3e ,f). Furthermore, breast-tumor cells from MTAG-TSLP-KO mice displayed decreased expression of Bcl-2 and Bcl-x L relative to that of their counterparts in MTAG mice ( Supplementary  Fig. 3e ). The human breast-tumor cell line MDA-MB-468 showed enhanced viability and increased expression of Bcl-2 when cultured in the presence of TSLP, whereas non-tumor breast epithelial-cell line MCF10A was not affected by such treatment ( Supplementary  Fig. 3f ,g). Although TSLP signaling affected the survival of breast tumors by regulating anti-apoptotic molecules, it did not affect the proliferation of breast-tumor cells, as depriving cells of TSLP in vitro (TSLP-or TSLPR-deficient 4T1 cells) or in vivo (TSLPRdeficient 4T1 cells in wild-type hosts, or TSLP-deficient 4T1 cells or TSLP-deficient hosts) did not change expression of the proliferation marker Ki67 in tumor cells ( Supplementary Fig. 3h ). Thus, TSLP signaling was important in maintaining the survival of breast-tumor cells, probably through the induction of anti-apoptotic molecules in vitro and in vivo.
Myeloid cells are the critical source of TSLP for maintaining tumor-cell survival. Next we sought to identify the TSLP-producing cell types during tumor progression. For this, we transplanted 4T1 cells into bone-marrow chimeras that lacked TSLP derived Articles NaTure ImmuNoLogy from either hematopoietic cells or stromal cells. Unexpectedly, we found that mice with TSLP deficiency in hematopoietic cells displayed smaller primary tumors and more tumor-cell death than that of mice with wild-type hematopoietic cells, but mice with TSLP deficiency in stromal cells did not ( Fig. 4a,b ), indicative of a role for hematopoietic cell-derived TSLP in the survival of tumor cells in vivo. We further found that neutrophils, Ly6C hi monocytes and tumor-associated macrophages, the three dominant hematopoietic cell populations in primary tumors, all expressed TSLP ( Fig. 4c,d ; gating strategies for these myeloid-cell populations in the primary tumor, Supplementary Fig. 4a ). As seen in human patients with breast cancer 32, 33 , neutrophil and Ly6C hi monocyte populations in blood were also considerably expanded in tumor-bearing mice ( Supplementary Fig. 4b-d ). Furthermore, these myeloid-cell populations in the blood of 4T1 tumor-bearing mice or MTAG mice had higher expression of Tslp than that of their coutnerparts in tumor-free mice ( Supplementary Fig. 4e ,f). We further assessed TSLP expression in classical monocytes from humans (equivalent to mouse Ly6C hi monocytes) 34 and found it was higher in patients with breast cancer than in healthy subjects ( Fig. 4e and Supplementary  Fig. 4g ,h). To determine whether TSLP from myeloid cells was involved in tumor progression, we transferred neutrophils isolated from tumor-bearing wild-type or TSLP-KO mice into tumor-bearing TSLP-KO mice. We found that neutrophils from tumor-bearing wild-type mice were able to restore the size of primary breast tumors in the TSLP-KO hosts, but those from tumor-bearing TSLP-KO mice were not (Fig. 4f ). The increase in primary tumor volume in TSLP-KO hosts that received neutrophils from wild-type donors was associated with increased tumor-cell survival (Fig. 4g ). To confirm that the decreased tumor-cell death was due directly to TSLP produced by the transferred neutrophils, we sorted wild-type or TSLP-KO neutrophils from tumor-bearing mice and cultured those cells with 4T1 cells. Wild-type neutrophils decreased the death of 4T1 cells, but TSLP-KO neutrophils did not, while TSLPR-KO 4T1 cells showed no response to either source of neutrophils. Co-culture of Ly6C hi monocytes with 4T1 cells or TSLPR-KO 4T1 cells produced a similar result ( Supplementary Fig. 4i ). Together these data demonstrated myeloid cells in a tumor setting as a critical source of TSLP for tumor survival in vitro and in vivo.
Breast tumor cell-derived IL-1α regulates TSLP expression in neutrophils.
As the myeloid-cell populations noted above from naive mice did not express or had low expression of TSLP, we hypothesized that a tumor cell-derived factor induced TSLP expression. It has been reported that IL-1 induces TSLP expression in epithelial cells 23 . We thus focused on IL-1α , as it is reported to be expressed in human breast tumors 25 . To explore the role of tumor-derived IL-1α in regulating TSLP expression by myeloid cells in vivo, we generated IL-1α -deficient 4T1 cells (generated with CRISPR-Cas9-GFP guide RNA 2-1 (4T1-Il1a -/-2-1cells) or 4-4 (4T1-Il1a -/-4-4 cells); Supplementary Fig. 5a ). We observed not only decreased expression of TSLP in neutrophils in tumor-bearing mice given transplantation of either clone of 4T1-Il1a -/cells (relative to that in their counterparts in mice given 4T1-M1 cells) but also increased cell death with reduced expression of Bcl-2 and Bcl-x L in 4T1-Il1a -/cells in the primary tumor, even though IL-1α deficiency did not alter the death of 4T1 cells in vitro (Fig. 5a-c and Supplementary Fig. 5b ). The primary tumors in those mice were also smaller than those of mice given transplantation of 4T1-M1 cells (Fig. 5d ). To determine if IL-1α directly affected TSLP expression in neutrophils, we sorted neutrophils from tumor-bearing mice at day 21 after transplantation and stimulated the cells with recombinant IL-1α . We found that such stimulation increased TSLP expression in the neutrophils in a dose-dependent manner (Fig. 5e ). Consistent with a report showing 
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NaTure ImmuNoLogy that IL-1α recruits neutrophils to the lungs during viral infection 35 , we observed less recruitment of neutrophils to primary tumors in mice given transplantation of 4T1-Il1a -/cells than in those given transplantation of 4T1-M1 cells (Fig. 5f ). These results demonstrated that IL-1α produced by tumor cells was able to induce TSLP production by myeloid cells that infiltrated the tumor and maintained tumor-cell survival and led to primary tumor progression.
TSLP is critical for maintaining the survival of metastases in the lungs. Having shown that TSLP derived from myeloid cells served as a survival factor for tumor cells at the primary tumor site, we then investigated if it also had a role in lung metastasis, which is the leading cause of cancer-associated mortality in breast cancer 36, 37 . Indeed, TSLP-KO mice given transplantation of 4T1 cells had not only smaller primary tumors but also fewer lung metastases than that of their wild-type counterparts (Fig. 6a,b) . To exclude the possibility that the reduction in lung metastases was due to a smaller primary tumor, we injected 4T1 cells intravenously into TSLP-KO mice and found these mice still had fewer lung metastases than that of their wild-type counterparts ( Supplementary Fig. 6a ). We quantified lung metastases in bone-marrow chimeras with TSLP deficiency either in hematopoietic cells or in stromal cells and found no difference between these two groups (Fig. 6c ), which suggested that the lack of either TSLP source could be compensated by the other. Although 4T1-Tslp -/-2-3 cells transplanted into wild-type mice displayed a primary tumor size similar to that of 4T1-M1 cells, they generated fewer lung metastases (Fig. 6d ). We further confirmed those results with MTAG mice and found that MTAG-TSLP-KO mice had fewer lung metastases than did MTAG mice (Fig. 6e ). Together these results suggested that TSLP present in the lungs, regardless of its source, was able to promote metastasis. Patients with breast cancer and a history of asthma experience more lung metastases, which indicates that increased TSLP production associated with asthma can increase metastasis 38, 39 . To test this, we transplanted 4T1 cells into a mouse strain that has increased amounts of lung-specific TSLP (SPC-TSLP mice) 40 . We found that 4T1 cells transplanted into SPC-TSLP mice showed greater metastasis to the lungs at both day 21 and day 28 after tumor injection, relative to the metastasis of such cells transplanted into wild-type mice, with no difference in primary tumor size ( Fig. 6f and Supplementary Fig. 6b ). We also found that mice given 4T1-Tslpr -/-4-6 cells, either transplanted in the fourth mammary gland or injected intravenously, showed fewer lung metastases than those of their counterparts given 4T1-M1 cells (Fig. 6g,h) . 4T1-Tslpr -/-4-6 cells transplanted intravenously into SPC-TSLP mice did not produce more lung metastases but produced a low number of lung metastases similar to that of 
NaTure ImmuNoLogy their counterparts transplanted into wild-type mice (Fig. 6h ). Furthermore, we observed fewer proliferating (Ki67 + ) 4T1-Tslpr -/-4-6 cells than proliferating 4T1-M1 cells in the lungs of wild-type mice given intravenous transplantion of tumor cells ( Fig. 6i ). Treating 4T1-GFP tumor-bearing mice with a neutralizing antibody to TSLP specifically in lungs (via intranasal administration) after lung metastasis had begun (day 14 after transplantation) reduced lung metastases but had no effect on the growth of the primary tumor ( Fig. 6j and Supplementary Fig. 6c ). Blockade of TSLP in the lungs not only reduced the survival of tumor cells by reducing the expression of Bcl-2 but also reduced their proliferation (Fig. 6k ).
Together these data demonstrated that TSLP derived from either tumor cells or non-tumor cells enhanced the survival and proliferation of tumor cell in the lungs and that local blockade of TSLP efficiently reduced tumor metastases.
Discussion
A role for TSLP in tumor development was first suggested by studies of human breast and pancreatic cancer in which TSLP was found to skew the tumor microenvironment toward a T helper type 2 inflammation that favors tumor protection 2,3,41 . Our study here revealed an unexpected but critical role for TSLP as an essential survival factor for breast-tumor cells. We further demonstrated that tumor-derived IL-1α was important in inducing TSLP expression by tumor-infiltrating myeloid cells. Notably, treating tumor-bearing mice with a neutralizing antibody to TSLP after tumor growth had begun inhibited subsequent tumor growth. In addition, lung-specific blockade of TSLP following the initiation of metastasis reduced the number of tumor metastases, which demonstrated a role for TSLP throughout the life of the tumor and provides a potential therapeutic target for all stages of breast cancer. TSLP signaling has been shown to increase cell survival through the induction of Bcl-2 or increased proliferation of responder cells, probably through phosphorylation of the transcript factor STAT5 ('signal transducer and activator of transcription 5') 6, [42] [43] [44] . Our findings support that idea, as we found TSLP-induced expression of Bcl-2 in the breast-tumor cells. As TSLP also has been reported to be upregulated in other human cancers [3] [4] [5] 7 , it is worth exploring if this pathway is also operative in other cancer types. The functional TSLPR complex was present on breast-tumor cells but not on normal breast tissue, which suggested that TSLPR expression is induced during neoplastic transformation. How the expression of TSLPR and IL-7Rα is regulated during this process remains unknown. A similar finding has been reported for colon cancer, in which the tumor, but not normal tissues, expressed a functional TSLPR 13 .
We also showed that, consistent with its role in the survival of the primary tumor, TSLP was critical for metastasis to the lungs. However, in the lungs, TSLP from any source was sufficient to promote metastasis. Together with the finding that TSLPR-deficient 4T1 cells failed to grow in the lungs following intravenous administration, these data support our model of TSLP as an obligate survival factor for tumor cells. However, a published study using the MTAG model has suggested that skin-derived TSLP, induced before the initiation of breast tumors, might have an inhibitory effect on the early development of breast tumors 12 . One possibility for the induction of different outcomes by TSLP in the same tumor model is that increased TSLP from the skin, before tumor induction, promotes local inflammation that leads to elimination of the tumor. 
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As published studies have found that elevated TSLP concentrations in the skin can inhibit local tumor growth 10, 11, 45 , it might act differently in the skin than in other sites. Such data suggest that elevated expression of TSLP, especially in the skin, before tumor initiation can inhibit tumor progression through the activation of local T cells, while TSLP induced following the establishment of a tumor is protective and promotes tumor survival . These data suggest that the role of TSLP in tumorigenesis can be complex and is determined by the specific TSLP-responding cell type(s) involved and its (their) importance in regulating tumor development.
The myeloid-cell production of TSLP was surprising, as published work has shown that TSLP is expressed predominantly by epithelial cells 20 . It is of note that only neutrophils from tumorbearing mice, not those from tumor-free mice, expressed substantial amounts of TSLP, while Ly6C hi monocytes from naive mice had low expression of TSLP, which was significantly greater in the tumor-bearing mice. In addition, classical monocytes derived from human patients with breast cancer showed increased TSLPproducing capacity, which suggested that signals from the tumor promoted the expression of TSLP by myeloid-lineage cells. Indeed, such myeloid cells in tumor settings have been reported to be functionally distinct from those in tumor-free condition 46 . Upregulation of TSLP expression might be one of the previously unknown features that favor tumor progression. Future studies should explore whether TSLP produced by myeloid cells is a universal feature of other tumor models or human cancers. We identified tumorderived IL-1α as one important factor capable of inducing TSLP expression in neutrophils. Interestingly, we observed a less-robust increase in TSLP expression by naive neutrophils sorted from tumor-free mice than by neutrophils isolated from tumor-bearing mice and stimulated with IL-1α in vitro (data not shown). Although these data indicate that other stimuli act coordinately with IL-1α to enhance TSLP expression, our data demonstrated that IL-1α was essential for neutrophil-derived TSLP. Future efforts should be aimed at exploring whether the induction of TSLP expression by IL-1α in neutrophils is universal or is specific to breast cancer, as IL-1α can be released by many other cancer types 24 . A published study using the 4T1 model has also suggested a role for TSLP in supporting tumor growth via direct signaling by CD4 + T cells 8 . While our results support the proposal of a role for TSLP in 4T1 cell-mediated tumor progression, our data demonstrated that TSLP exerted its pro-tumor properties by acting on tumor cells. Interestingly, we observed that TSLPR deficiency in all T cells did not affect tumor growth; in fact, primary tumor growth was somewhat greater in these mice with TSLPR deficiency in total T cells than in control mice (data not shown), in agreement with the proposal that TSLP signaling in T cells might inhibit tumors [10] [11] [12] . Finally, the 'rescue' of tumor growth by the transfer of TSLP-sufficient neutrophils, but not by neutrophils in which TSLP was deleted, demonstrated that TSLP from non-tumor cells was the primary driver in overall tumor progression.
In summary, our data have demonstrated that breast tumors produce IL-1α , which then acts to induce subsequent production of TSLP by tumor-infiltrating myeloid cells, with TSLP then acting as a critical survival factor for the tumor. These data suggest that blockade of TSLP or IL-1α might be an effective therapeutic intervention in metastatic breast cancer to not only block the growth of the primary tumor but also to inhibit metastasis to the lung. Corresponding author(s): Steven F. Ziegler
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Experimental design 1. Sample size
Describe how sample size was determined.
No statistical method was used to predetermine sample size. Sample size was chosen to achieve a greater than 95% probability of identifying, by two-tailed ttest, an effect of >20% between groups. In general, two or three independent experiments were conducted with at least two biological replicates or technical replicates where applicable. For most in vivo tumor experiments, at least three to five animals per group were used in each experiment.
Data exclusions
Describe any data exclusions.
No data was excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No special randomization tool was used to allocate samples into groups when starting experiments, but the following covariates were controlled: age, gender, and littermate status.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were blinded to group allocation at endpoint and random sample number was given to mouse samples when taking down mice and acquiring data. When counting number of tumor metastases in lungs, sample numbers were randomized again by another lab member who was blinded to mouse groups. For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials c. Report whether the cell lines were tested for mycoplasma contamination.
4T1 cell line has been tested as free of mycoplasma contamination.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
All cell lines used in our study were not found in the database of ICLAC, Version 8.0 Table 1 , Publication Data 1/12/2016.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study.
All 4T1 experiments were performed in 8-to10-week-old female BALB/c mice. CD45.2+ WT mice were purchased from Charles River Laboratories. TSLP-KO, and SPC-TSLP40 mice were all backcrossed to BALB/c background for more than 10 generations. MTAG in C57BL/6 background mice were provided by S. Abrams (Roswell Park Cancer Institute). MTAG/TSLP-KO mice were generated from crossing MTAG mice to TSLP-KO mice in C57BL/6 background mice. All experiments were performed as approved by Benaroya Research Institute animal facility IACUC. All mice were bred and housed in specific-pathogen free conditions in Benaroya Research Institute animal facility.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
For the experiment of examining TSLPR expression on human breast tumors, all breast cancer patients were female, age range 34-70 yr old, and were diagnosed with invasive breast carcinoma. Detailed information is stated in Supplementary  Fig. 1b . For the experiment to assess TSLP expression in monocytes in healthy vs. breast cancer patients, breast cancer patients were all female and with invasive breast carcinoma. Healthy control for this were also all female donors, age range 40-66 yr old. Detailed information is stated in supplementary Fig. 4h .
Corresponding author(s): Steven F. Ziegler
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Data presentation
For all flow cytometry data, confirm that:
1. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
2. The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
3. All plots are contour plots with outliers or pseudocolor plots. Purity for post-sort cells was all above 85 %. If purity is lower than 85 % due to some mechanical issue, cells will not be used in experiments. Average cell purity in each experiments are shown below: Fig. 2c : purity for 4T1-GFP cells was 92 %; for tumor cells in MTAG primary tumors was 98 %. For Fig. 3f , 4T1-GFP cell purity was 90 %. For Fig. 4d , purity was 89 % for TAMs, 88 % for Ly6Chi monocytes, and 96 % for neutrophils. For Fig. 4e , purity for human classical monocytes was 88 %. For Fig. 5a , purity was 96 % for splenic neutrophils and 97 % for tumor neutrophils. For Fig. 5d , neutrophil purity was 93 %. For supplementary Fig. 3e , sorted tumor cell purity was 92 %. For supplementary Fig. 4e , purity was 88 % for Ly6Chi monocytes and 92 % for neutrophils. For supplementary Fig. 4f , sorted neutrophil purity was 94 %. For supplementary Fig. 4i , purity was 90 % for neutrophils and was 86 % for Ly6Chi monocytes. For supplementary Fig. 5c , sorted 4T1 cell purity was 91 %.
9. Describe the gating strategy used. All markers used for gating show a clear separation of the negative and positive population.
For all experiments, cells were first gated based on FSC-A and SSC-A to exclude debris and noise signals from machine. Doublets were excluded by FSC-W vs. FSC-A gating and then SSC-W vs. SSC-A gating. See top panel in Supplementary Fig. 2a as an example in mouse tissue and in
